title: Serum pepsinogen I/II ratio is correlated with albuminuria in patients with type 2 diabetes.
abstract: Helicobacter pylori infection, which is a common cause of atrophic gastritis, has been reported to represent a causal factor increasing the vascular damage and consequent albuminuria. On the other hand, decreased serum pepsinogen (PG) I/II ratio can be used to assess gastric mucosal atrophy. To the best of our knowledge, there are no studies investigating the correlation between PG I/II ratio and diabetic nephropathy. Therefore, we investigated a relationship between PG I/II ratio and degree of urinary albumin excretion (UAE) in patients with type 2 diabetes. We evaluated relationships between PG I/II ratio and degree of UAE or estimated glomerular filtration rate as well as various factors, including age, body mass index, blood pressure, hemoglobin A1c, serum lipid concentrations, uric acid or C-reactive protein in 333 consecutive patients with type 2 diabetes. PG I/II ratio correlated positively with logarithm of UAE in all patients (r = 0.174, P = 0.0016) and in patients without Helicobacter pylori infection (r = 0.352, P < 0.0001). Multiple regression analysis identified that PG I/II ratio correlated independently with logarithm of UAE in all patients (β = 0.264, P = 0.0005) and in patients without Helicobacter pylori infection (β = 0.295, P = 0.0022). These data suggest that serum PG I/II ratio is correlated with diabetic nephropathy.
authors.affiliation: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
authors.forename: Takafumi
authors.initials: T
authors.lastname: Senmaru
authors.forename: Michiaki
authors.initials: M
authors.lastname: Fukui
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kuroda
authors.forename: Muhei
authors.initials: M
authors.lastname: Tanaka
authors.forename: Emi
authors.initials: E
authors.lastname: Ushigome
authors.forename: Kazumi
authors.initials: K
authors.lastname: Sakabe
authors.forename: Naoko
authors.initials: N
authors.lastname: Nakanishi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Mineoka
authors.forename: Mai
authors.initials: M
authors.lastname: Asano
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamazaki
authors.forename: Goji
authors.initials: G
authors.lastname: Hasegawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Nakamura
mesh_terms: D000368:Aged; D000419:Albuminuria / Q000150:complications*; D000465:Algorithms; D000907:Antibodies, Bacterial / Q000032:analysis; D015415:Biomarkers / Q000097:blood / Q000652:urine; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000276:immunology / Q000382:microbiology; D003928:Diabetic Nephropathies / Q000097:blood / Q000453:epidemiology / Q000503:physiopathology* / Q000652:urine; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000276:immunology / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007668:Kidney / Q000276:immunology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D020116:Pepsinogen A / Q000097:blood*; D020115:Pepsinogen C / Q000097:blood*; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D000907:Antibodies, Bacterial; D015415:Biomarkers; D020115:Pepsinogen C; D020116:Pepsinogen A